Michael W Gast

US Patent:

6451778, Sep 17, 2002

Filed:

Jul 2, 1997

Appl. No.:

08/886072

Inventors:

Michael J. Gast - Phoenixville PA

Assignee:

Wyeth - Madison NJ

International Classification:

A61K 3156

US Classification:

514170, 514843

Abstract:

This invention provides a method of contraception which comprises administering to a female of child beating age for a combination of a progestin at a daily dosage of 40-500 g trimegestone, 250 g-4 mg dienogest, or 250 g-4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 g ethinyl estradiol for 23-25 days beginning on day 1 of the menstrual cycle, and wherein the same dosage of the progestin and estrogen combination is administered in each of the 23-25 days.

US Patent:

6479475, Nov 12, 2002

Filed:

Jul 2, 1997

Appl. No.:

08/887163

Inventors:

Michael J. Gast - Phoenixville PA

Assignee:

Wyeth - Madison NJ

International Classification:

A61P 1518

US Classification:

514170, 514843, 514181, 514182

Abstract:

This invention provides a method of contraception which comprises administering to a female of child bearing age for 23-25 consecutive days, a first phase combination of a progestin at a daily dosage of 40-500 g trimegestone, 250 g-4 mg dienogest, or 250 g-4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 g ethinyl estradiol for 3-8 days beginning on day 1 of the menstrual cycle, wherein the same dosage of the progestin and estrogen combination is administered in each of the 3-8 days, a second phase combination of a progeslin at a daily dosage of 40-500 g trimegestone, 250 g-4 mg dienogest, or 250 g-4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 g ethinyl estradiol, for 4-15 days beginning on the day immediately following the last day of administration of the first phase combination, wherein the same dosage of the progestin and estrogen combination is administered in each of the 4-15 days, and a third phase combination of a progestin at a daily dosage of 40-500 g trimegestone, 250 g-4 mg dienogest, or 250 g-4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 g ethinyl estradiol, for 4-15 days beginning on the day immediately following the last day of administration of the second phase combination, wherein the same dosage of the progestin and estrogen combination is administered in each of the 4-15 days provided that the daily dosage of the combination administered in the first phase is not the same as the daily dosage of the combination administered in the second phase and that the daily dosage of the combination administered in the second phase is not the same as the daily dosage of the combination administered in the third phase.

US Patent:

20020061875, May 23, 2002

Filed:

Nov 21, 2001

Appl. No.:

09/989074

Inventors:

Michael Gast - Phoenixville PA, US
Christopher Miller - Wayne PA, US

Assignee:

American Home Products Corporation - Madison NJ

International Classification:

A61K031/55
A61K031/551
A61K031/5377
A61K031/506
A61K031/541
A61K031/501
A61K031/496
A61K031/454
A61K031/427
A61K031/425
A61K031/422
A61K031/42
A61K031/4178
A61K031/404

US Classification:

514/212080, 514/217080, 514/218000, 514/228200, 514/233500, 514/252060, 514/254090, 514/256000, 514/323000, 514/365000, 514/372000, 514/385000, 514/397000, 514/414000

Abstract:

This invention provides a method of providing contraception which comprises administering to a female of child bearing age a combination of a non-uterotrophic anti-estrogen and a progestin for 28 days per 28-day menstrual cycle.

US Patent:

20070238713, Oct 11, 2007

Filed:

Apr 5, 2007

Appl. No.:

11/696917

Inventors:

Michael GAST - West Chester PA, US
Eileen HELZNER - Villanova PA, US

Assignee:

WYETH - Madison NJ

International Classification:

A61K 31/56
A61K 31/57

US Classification:

514170000

Abstract:

The present invention relates to methods for the prevention and treatment of conditions arising from local estrogen deficiency, such as dyspareunia, vulvar atrophy, vaginal atrophy, vaginal dryness, vulvar itching, vaginal itching, vulvar burning, vaginal burning, vulvar dystrophy, atrophic vaginitis or menopausal sexual dysfunction. In some embodiments, the methods include systemic, for example oral, administration of an estrogen, such as conjugated estrogens, and a progestagen, such as MPA, contemporaneously with local administration of an estrogen, for example conjugated estrogens. In some embodiments, the methods include the oral administration of conjugated estrogens and MPA, and the vulvar, vaginal, or vulvar and vaginal administration of conjugated estrogens, for example in a cream.

US Patent:

57474800, May 5, 1998

Filed:

Apr 17, 1997

Appl. No.:

8/839286

Inventors:

Michael J. Gast - Phoenixville PA

Assignee:

American Home Products Corporation - Madison NJ

International Classification:

A61K 3156

US Classification:

514179

Abstract:

This invention provides a method of contraception which comprises administering to a female of child bearing age for 28 consecutive days, a first phase combination of a progestin at a daily dosage equivalent in progestational activity to 40-125. mu. g levonorgestrel and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20. mu. g ethinyl estradiol for 3-8 days beginning on day 1 of the menstrual cycle, wherein the same dosage of the progestin and estrogen combination is administered in each of the 3-8 days, a second phase combination of a progestin at a daily dosage equivalent in progestational activity to 40-125. mu. g levonorgestrel and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20. mu. g ethinyl estradiol, for 4-15 days beginning on the day immediately following the last day of administration of the first phase combination, wherein the same dosage of the progestin and estrogen combination is administered in each of the 4-15 days, a third phase combination of a progestin at a daily dosage equivalent in progestational activity to 40-125. mu. g levonorgestrel and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20. mu.

US Patent:

59848901, Nov 16, 1999

Filed:

Sep 22, 1997

Appl. No.:

8/937318

Inventors:

Michael J. Gast - Phoenixville PA
Neil W. Miller - Newtown PA
John M. Patton - Coatesville PA

Assignee:

American Home Products Corporation - Madison NJ

International Classification:

A61M 3100

US Classification:

604 60

Abstract:

The present invention provides improved devices for inserting solid materials under a tissue, the devices particularly containing a penetration guide means designed to facilitate the implantation by limiting the insertion of the implants to positions under and substantially parallel to the plane of the tissue.

US Patent:

63263920, Dec 4, 2001

Filed:

Nov 3, 1998

Appl. No.:

9/185058

Inventors:

Michael J. Gast - Phoenixville PA
Christopher P. Miller - Wayne PA

Assignee:

American Home Products Corporation - Madison NJ

International Classification:

A61K 31405
A61K 3156

US Classification:

514415

Abstract:

This invention provides a method of providing contraception which comprises administering to a female of child bearing age a combination of a non-uterotrophic anti-estrogen and a progestin for 28 days per 28-day menstrual cycle.

US Patent:

58885439, Mar 30, 1999

Filed:

Jul 2, 1997

Appl. No.:

8/886070

Inventors:

Michael J. Gast - Phoenixville PA

Assignee:

American Home Products Corporation - Madison NJ

International Classification:

A61K 920
A61K 3156

US Classification:

424464

Abstract:

This invention provides a method of contraception which comprises administering to a female of child bearing age for 23-25 consecutive days, a first phase combination of a progestin at a daily dosage of 40-500. mu. g trimegestone, 250. mu. g-4 mg dienogest, or 250. mu. g-4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20. mu. g ethinyl estradiol for 9-13 days beginning on day 1 of the menstrual cycle, wherein the same dosage of the progestin and estrogen combination is administered in each of the 9-13 days, and a second phase combination of a progestin at a daily dosage of 40-500. mu. g trimegestone, 250. mu. g-4 mg dienogest, or 250. mu. g-4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20. mu. g ethinyl estradiol, for 11-15 days beginning on the day immediately following the last day of administration of the first phase combination, wherein the same dosage of the progestin and estrogen combination is administered in each of the 11-15 days, provided that the daily dosage of second phase progestin is greater than the daily dosage of the first phase progestin and that the daily dosage of the second phase estrogen is greater than or equal to the daily dosage of the first phase estrogen.